U09.9 U08.9
Conditions
Interventions
Group 1: Cohort I: clinical collective of hospitalized patients
Group 2: Cohort II: outpatient collective
Group 3: Cohort III: controls, NAKO sample
Sponsors
Universitätsklinikum Düsseldorf
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: - Main residence in North Rhine-Westphalia in the area of the cities of Aachen, Bonn, Düsseldorf, Essen, Cologne or Münster - 18 - 75 years old - Proof of a survived SARS-CoV-2 infection (PCR-test) - Infection in the period from March 1st, 2021 (1st recruitment round) - the time of infection is at least 3 months back (inpatients: date of the COVID-19-related inpatient admission day; outpatients: date of the first positive PCR test) - The person is able to take part in the survey and the examinations - sufficient knowledge of the German language or support from an interpreter
Exclusion criteria
Exclusion criteria: - Active SARS-CoV-2 infection and / or time of infection is less than 3 months back (inpatients: Date of admission; outpatients: date of the first positive PCR-test). Inclusion possible at a later date. - Lack of diagnostic evidence of SARS-CoV-2 infection using a PCR test - Person is unable to give written informed consent - Other reasons that study participants can not visit the study center, e.g. due to logistical reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -Evaluate long term cardial, lung and liver function (abdominal sonography, echocardiocraphy, pulmonary function examination, blood tests) -Changes in Quality of Life, physically and mental health, functioning and activity an public health aspects (multiple validated questionnaires) -medical resource use (questionnaire) -cognitive/neurological impairment (neuropsychological assessment) Time schedule: At 3, 6, 12, 18, 24, 30 and 36 month after SARS-CoV-2-Infection | — |
Secondary
| Measure | Time frame |
|---|---|
| -Patient characteristics and differences in those with/without Long-Covid complications (blood tests, genetic analysis, humoral and cellular immunity directed against SARS-CoV-2; immunological factors responsible for the observed long-term effects) -Definition and characteristics of the early and late COVID-19 complications -Evaluation of Long-Covid depending on the severity of the course of COVID-19 and comorbidities Time schedule: At 3, 6, 12, 18, 24, 30 and 36 month after SARS-CoV-2-Infection | — |
Countries
Germany
Contacts
Public ContactAlexander Mertens
Universitätsklinikum Düsseldorf
Outcome results
None listed